Iro H, Waldfahrer F, Altendorf-Hofmann A, Weidenbecher M, Sauer R, Steiner W
Department of Otorhinolaryngology-Head and Neck Surgery, Saarland University, Homburg, Germany.
Arch Otolaryngol Head Neck Surg. 1998 Nov;124(11):1245-50. doi: 10.1001/archotol.124.11.1245.
To determine the role of transoral laser resection of supraglottic carcinomas.
Retrospective unicenter study of the oncologic results of transoral carbon dioxide laser microsurgery for supraglottic carcinomas performed between February 1979 and December 1993. Median follow-up was 37 months.
University hospital academic tertiary referral center.
We reviewed the medical records of 141 patients (a consecutive sample of 131 men and 10 women; mean age, 60 years) with histologically proven supraglottic carcinomas undergoing transoral laser surgery, possibly in combination with neck dissection or radiotherapy. Stage distribution of patients was as follows: stage I, 23.4%; stage II, 25.5%; stage III, 16.3%; and stage IV, 34.8% (according to the Union Internationale Contre le Cancer staging system).
Recurrence-free survival rates and local and regional recurrence rates.
Five-year recurrence-free survival rates were as follows: the whole case load, 65.7%; stage I, 85.0%; stage II, 62.6%; stage III, 74.2%; and stage IV, 45.3%, according to the Union Internationale Contre le Cancer staging system. The local and regional recurrence rates were 16.3% and 9.9%, respectively.
The oncologic results of transoral carbon dioxide laser surgery are satisfying if clean surgical margins (R0 resection) can be reached. In patients in whom tumor-free margins are not achieved (R1 and R2 resection) and transoral revision is not possible, transcervical procedures (partial or total laryngectomy) should be performed. The indication for transoral supraglottic laryngectomy in T3 lesions should be considered with restraint.
确定经口激光切除声门上癌的作用。
对1979年2月至1993年12月间行经口二氧化碳激光显微手术治疗声门上癌的肿瘤学结果进行回顾性单中心研究。中位随访时间为37个月。
大学医院学术三级转诊中心。
我们回顾了141例经组织学证实为声门上癌且接受经口激光手术(可能联合颈部清扫术或放疗)患者的病历(连续样本,131例男性和10例女性;平均年龄60岁)。患者的分期分布如下:I期,23.4%;II期,25.5%;III期,16.3%;IV期,34.8%(根据国际抗癌联盟分期系统)。
无复发生存率以及局部和区域复发率。
根据国际抗癌联盟分期系统,五年无复发生存率如下:全部病例,65.7%;I期,85.0%;II期,62.6%;III期,74.2%;IV期,45.3%。局部和区域复发率分别为16.3%和9.9%。
如果能达到切缘阴性(R0切除),经口二氧化碳激光手术的肿瘤学结果是令人满意的。对于未实现无瘤切缘(R1和R2切除)且无法经口进行修正手术的患者,应行颈部手术(部分或全喉切除术)。对于T3病变,经口声门上喉切除术的适应证应谨慎考虑。